Assessing the effectiveness of upadacitinib for treating Crohn's disease in Japan

A Post-marketing Non-interventional Study for Upadacitinib in Patients With Moderately to Severely Active Crohn's Disease (CD) in Japan

Observational AbbVie · NCT06023030

This study is testing if upadacitinib can help teenagers and adults in Japan with moderate to severe Crohn's disease feel better and stay safe while using the medication.

Quick facts

Study typeObservational
Enrollment240 (estimated)
Ages15 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsupadacitinib
Locations104 sites (Anjo-shi, Aichi-ken and 103 other locations)
Trial IDNCT06023030 on ClinicalTrials.gov

What this trial studies

This observational study evaluates the safety and effectiveness of upadacitinib in treating adolescents and adults with moderate to severe active Crohn's disease in Japan. Participants will receive upadacitinib as prescribed by their healthcare providers, and their disease activity and any adverse events will be monitored over a period of up to 64 weeks. Approximately 240 participants will be enrolled, and the study aims to reflect real-world clinical practices without imposing additional burdens on participants.

Who should consider this trial

Good fit: Ideal candidates include adolescents and adults diagnosed with moderately to severely active Crohn's disease who have been prescribed upadacitinib.

Not a fit: Patients who are currently participating in another interventional clinical research or for whom upadacitinib is contraindicated may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness and safety of upadacitinib for patients with Crohn's disease.

How similar studies have performed: Other studies have shown positive outcomes with upadacitinib for Crohn's disease, indicating that this approach is supported by prior evidence.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosed with moderately to severely active Crohn's disease (CD).
* Has been prescribed upadacitinib for CD as per most current local approved label after its approval for CD in Japan.
* Within 14 days from the commencement of upadacitinib induction treatment for CD at the participating institution.

Exclusion Criteria:

* Currently participating in another interventional clinical research.
* Participants for whom upadacitinib is contraindicated.
* Has been treated with upadacitinib for CD before and continue treatment with upadacitinib for CD at the participation to this study.

Where this trial is running

Anjo-shi, Aichi-ken and 103 other locations

+54 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Crohn's DiseaseCrohn's diseaseUpadacitinib
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.